Cystatin C and target organ damage in arterial hypertension


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Aim. Characteristics of interrelations between serum cystatin C level and target organ damage in arterial hypertension. Methods. 94 patients with arterial hypertension (age 30 - 65 years) were included into the study. Body mass index (BMI), proteinuria, carotid intima-media thicknesss, serum cytstatin C levels were determined. Echocardiography and 24-hour blood pressure monitoring were performed. Results. Median serum cystatin C level was (і029,4 ng/ml [772; 1216], min - 350 ng/ml, maximum 2371,95 ng/ml). Serum cystatin C level was asscociated with age, obesity, stage of arterial hypertension, glomerula filtration rate, left ventricular mass myocardial index, carotid intima-media thickness. Conclusion. Serum cystatin C level is associated with target organ damage in arterial hypertension.

Texto integral

Acesso é fechado

Bibliografia

  1. Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. Hypertension 2003; 42:2: 1206-1252.
  2. Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония 2000: ключевые аспекты диагностики, дифференциальной диагностики, профилактики, клиники и лечения. М., 2000; 71-92.
  3. Vanholder R., Massy Z., Argiles A. et al. Chronic kidney disease as cause of cardiovascular mobility and mortality. Nephrol Dial Transplant 2005; 20:6: 1048-1056.
  4. Segura J., Campo C., Gil P. et al. Development of Chronic Kidney Disease and Cardiovascular Prognosis in Essential Hypertensive Patients. J Am Soc Nephrol 2004; 15:6: 1616-1622.
  5. Valderrabano F., Gomes-Campdera F., Jones E. Hypertension as cause of end-stage renal disease: lessons from international registries. Kidney Int 1998; 68:12: 60-66.
  6. Резниченко Н.Е., Панфилова Е.Ю., Данковцева Е.Н. и др. Возможности использования цистатина С в кардиологии. Медицинский алфавит. Больница. 2009; 2: 23-26.
  7. Laterza O.F., Price C.P., Scott M. G. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48:699-707.
  8. Larsson A., Malm J., Grubb A. et al. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest. 2004;64:25-30.
  9. Bokenkamp A., Domanetzki M., Zinck R. et al. Cystatin C: a new marker of glomerular filtration rate in children independent of age and height. Pediatrics. 1998;101:875-881.
  10. Fliser D., Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001; 37:79-83.
  11. Вельков В.В. Цистатин С: Новые возможности и новые задачи для лабораторной диагностики. (Часть 1). Клинико-лабораторный консилиум. 2010; 5: 23-31.
  12. Tonelle C. et al. Partial amino acid sequence of two forms of human postgamma globulin. Biochemical Biophysical Research Communications. 1979; 86(3): 613-619.
  13. Rawlings N.D., Barrett A.J. Evolution of proteins of the cystatin superfamily. Journal of Molecular Evolution. 1990; 30: 60- 71.
  14. Hall A. et al. Structural basis for the biological specificity of cystatin C. J Biological Chemistry. 1995; 270: 5115-5121.
  15. Brown W.M., Dziegielewska K.M. Friends and relations of the cystatin superfamily - new members and their evolution. Protein Science. 1997; 6: 5-12.
  16. Finney H., Newman D.J., Thakkar H. et al. Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch. Dis. Child. 2000; 82 (1): 71-75.
  17. Filler G., Bцkenkamp A., Hofmann W. et al. Clin. Biochem. 2005;38 (1:1-8.
  18. Ognibene A., Mannucci E., Caldini A. et al. Cystatin C reference values and aging. Clin. Biochem. 2006;39(6):658-661.
  19. Croda-Todd M.T., Soto-Montano X.J. et al. Adult cystatin C reference intervals determined by nephelometric immunoassay. Clin. Biochem. 2007; 40 (13-14): 1084-1087.
  20. Köttgen A., Selvin E., Stevens L.A. et al. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008; 51(3):385-394.
  21. Диагностика и лечение артериальной гипертензии. //Национальные клинические рекомендации ВНОК. М:2008, с.23.
  22. Арутюнов Г.П., Оганезова Л.Г. Гиперфильтрация у больных артериальной гипертензией: результаты эпидемиологического исследования. Тер. арх. 2009; 8: 24-30.
  23. Оганезова Л.Г. Почечная функция у кардиологических больных: оптимальные методы оценки. Кардиология сегодня. 2012; 1:5.
  24. Вельков В.В. Цистатин С: Новые возможности и новые задачи для лабораторной диагностики. (Часть 2). Клинико-лабораторный консилиум. 2011; 1: 27-38.
  25. Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-226.
  26. Palatini P., Benetti E., Zanier A. et al. Cystatin C as predictor of microalbuminuria in the early stage of hypertension. Nephron Clin Pract. 2009; 113(4): 309-14.
  27. Naour N., Fellahi S., Renucci J.F. et al. Potential Contribution of Adipose Tissue to Elevated Serum Cystatin C in Human Obesity. Obesity (Silver Spring). 2009; 17(12): 2121-2126.
  28. Liu J., Sukhova G.K., Sun J.S. et al. Lysosomal cysteine proteases in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 1359-1366.
  29. Lutgens S.P., Cleutjens K.B., Daemen M.J. et al. Cathepsin cysteine proteases in cardiovascular disease. Faseb J. 2007; 21: 3029-3041.
  30. Sukhova G.K., Wang B., Libby P. et al. Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ. Res. 2005; 96: 368-375.
  31. Bengtsson E., To K., Hakansson T. et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2151-2156.
  32. Patel P.C., Ayers C.R., Murphy S.A. et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail. 2009; 2(2): 98-104.
  33. Moran A., Katz R., Smith N.L. et al. Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail. 2008; 14(1):19-26.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies